Navigation Links
Published Results Using AtriCure Minimally Invasive Products
Date:10/16/2007

WEST CHESTER, Ohio, Oct. 16 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation products, today announced that results reporting on the Company's proprietary minimally invasive products, which physicians have adopted to treat atrial fibrillation (AF), were published in the Journal of Cardiovascular Electrophysiology by Dr. James H. McClelland, an electrophysiologist, and colleagues from the Oregon Heart and Vascular Institute.

The authors reported the results from 20 AF patients. Based on the use of 30-day continuous monitoring at one-year follow-up, 87.5% of the paroxysmal and persistent AF patients and 75% of overall patients were free from AF and left atrial arrhythmias and were also off anti-arrhythmic drugs. There were no reports of major complications.

Dr. James H. McClelland commented, "These data suggest that epicardial bipolar ablation, along with guided ablation of the ganglionic plexi, is a promising potential treatment for patients with paroxysmal and persistent AF and a more extensive ablation treatment is likely required to treat patients with more permanent forms of AF."

"These results support our confidence in our ability to expand the treatment options for those patients who suffer from AF and our commitment to pursuing AF approvals for our products from the Food and Drug Administration (FDA)," said David J. Drachman, AtriCure's President and Chief Executive Officer. "During the first quarter of 2008, we have plans to investigate new products which will expand the ablation procedure. We believe that these new products will provide a superior treatment alternative for persistent and permanent AF patients, patients who fail catheter ablation procedures and patients who are at higher risk for strokes due to their AF."

About AtriCure, Inc.

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices designed to create precise lesions, or scars, in cardiac, or heart, tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps, for the ablation, or destruction, of soft tissues in general and cardiac related surgical procedures, but to date has not cleared or approved the system for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing,

stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure's products. Forward-looking statements are based on AtriCure's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Largest Ever Study of Genetics Behind Common Diseases Published
2. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
3. Findings on Dangerous Parasite, Toxoplasma Gondii Published
4. Siddha Medicine Texts to Be Published in English
5. Experimental treatment for Ebola Virus Shows promising results in mice
6. Hormone Deficiency Results In Miscarriage
7. Gleevec gets hopeful results
8. Breast Implants May Interfere With The Interpretation Of Mammogram Results
9. DNA Testing For More Accurate Results
10. Operating on a Beating Heart Yields Better Results For Blocked Heart Arteries
11. IVF results may be affected by stress and other related factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
Breaking Medicine Technology: